Daniel Pölöske et al. (2024) Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma Crossref. (doi: 10.1002/hem3.70001)

Tobias Suske et al. (2024) Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia Daniel Pölöske, PhD. ISSN 1558-8238 (doi: 10.1172/jci168536)

Aaron B. Keeley et al. (2024) Electrophilic MiniFrags Revealed Unprecedented Binding Sites for Covalent HDAC8 Inhibitors Daniel Pölöske, PhD. ISSN 1520-4804 (doi: 10.1021/acs.jmedchem.3c01779)

Helena Sorger et al. (2022) Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T‐cell lymphoma Daniel Pölöske, PhD. ISSN 1757-4684 (doi: 10.15252/emmm.202115200)

Harsimran Kaur Garcha et al. (2022) High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma Daniel Pölöske, PhD. ISSN 1424-8247 (doi: 10.3390/ph15111321)

Javier Bregante, Anna Schönbichler, Daniel Pölöske, Lina Degenfeld-Schonburg, Garazi Monzó Contreras, Emir Hadzijusufovic, Elvin D. de Araujo, Peter Valent, Richard Moriggl, Anna Orlova (2021) Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia Daniel Pölöske, PhD. ISSN 2072-6694 (doi: 10.3390/cancers13246181)

Manuel Matzinger, Katrin Fischhuber, Daniel Pölöske, Karl Mechtler, Elke H. Heiss (2020) AMPK leads to phosphorylation of the transcription factor Nrf2, tuning transactivation of selected target genes Daniel Pölöske, PhD. ISSN 2213-2317 (doi: 10.1016/j.redox.2019.101393)